Successful Remission of Refractory Plantar Warts with Cantharidin Plus in an Immunosuppressed Patient
Main Article Content
Keywords
plantar warts, verruca plantaris, verruca vulgaris, immunosuppression, human papillomavirus, transplant
Abstract
Organ transplant patients on immunosuppressive therapies are susceptible to developing refractory human papillomavirus (HPV) infections including cutaneous warts. These warts are known to respond to conservative treatment modalities in the immunocompetent but are often refractory to multiple treatments in the immunosuppressed. Here we report a case of an immunosuppressed adult with plantar warts recalcitrant to numerous therapies that was ultimately treated successfully with cantharidin-podophyllotoxin-salicylic acid (CPS) monotherapy. After 19 treatment sessions over a 16-month time period, complete resolution was achieved. CPS may be a promising treatment modality in cases of severe, refractory verruca plantaris such as those seen in our immunosuppressed patient.
References
2. Dyall‐Smith D, Trowell H, Dyall‐Smith ML. Benign human papillomavirus infection in renal transplant recipients. International journal of dermatology. 1991;30(11):785-789.
3. Joly P, Bastuji-Garin S, Frances C, et al. Squamous cell carcinomas are associated with verrucokeratotic cutaneous lesions but not with common warts in organ-transplant patients. A case-control study. Transplantation. 2010;89(10):1224-1230.
4. D’Souza GF, Zins JE. Severe plantar warts in an immunocompromised patient. New England Journal of Medicine. 2017;377(3):267-267.
5. Dobson JS, Harland CC. Pulsed dye laser and intralesional bleomycin for the treatment of recalcitrant cutaneous warts. Lasers in surgery and medicine. 2014;46(2):112-116.
6. Lee AN, Mallory SB. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. Journal of the American Academy of Dermatology. 1999;41(4):595-599.
7. Nofal A, Adel L, Fawzy M, Elkholy BM. Intralesional immunotherapy for multiple recalcitrant plantar warts: Candida antigen is superior to intralesional purified protein derivative. Dermatologic Therapy. 2022:e15440.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.